Literature DB >> 19204906

Analysis of inherited genetic variations at the UGT1 locus in the French-Canadian population.

Vincent Ménard1, Hugo Girard, Mario Harvey, Louis Pérusse, Chantal Guillemette.   

Abstract

The UDP-glucuronosyltransferase UGT1 locus is composed of nine exon 1s, each flanked by a unique promoter region, and common exons (2, 3, 4, and the alternatively spliced exons 5a and 5b). Here, we characterized the genetic architecture of the UGT1 gene in a Caucasian sample. Overall, 98 variations in regulatory domains, exons and exon-intron boundaries were genotyped in 254 unrelated subjects, including 12 unreported UGT1 polymorphisms. We determined allele frequencies, computed pairwise linkage disequilibrium (LD), and inferred haplotypes; this thorough analysis yielding a limited number of common UGT1 haplotypes. Moreover, only 17 haplotype tagging single nucleotide polymorphisms (htSNPs) are required to capture most of the allelic diversity of the locus. Four haplotype blocks were inferred: Block 9/6 (UGT1A9, UGT1A7 and UGT1A6), Block 4 (UGT1A4), Block 3/1 (UGT1A3 and UGT1A1), and Block C (3'UTR). A high level of linkage exists between Blocks 9/6 and 3/1, while the 3'UTR SNPs are genetically isolated. The most common haplotype (16.5%) presents multiple deleterious alleles, mainly 1A1*28, 1A3*2, 1A6*2, and 1A7*4. More interestingly, we reveal the co-occurrences of multiple deleterious variations, some of which could be associated with interindividual differences in glucuronidation. Comparison with the HapMap data set demonstrated differences in haplotypic diversity between ethnic samples, but similarity between Caucasian cohorts, as observed previously. This report provides relevant data for further pharmacogenomic studies. (c) 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19204906     DOI: 10.1002/humu.20946

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  13 in total

1.  UDP-glucuronosyltransferase 1A4 (UGT1A4) polymorphisms in a Jordanian population.

Authors:  Nancy Hakooz; Sameh Alzubiedi; Al-Motassem Yousef; Tawfiq Arafat; Rana Dajani; Nidaa Ababneh; Said Ismail
Journal:  Mol Biol Rep       Date:  2012-02-25       Impact factor: 2.316

2.  Influence of UDP-glucuronosyltransferase polymorphisms on valproic acid pharmacokinetics in Chinese epilepsy patients.

Authors:  Xiao-Man Chu; Li-Fang Zhang; Guang-Ji Wang; Shen-Ning Zhang; Jia-Hui Zhou; Hai-Ping Hao
Journal:  Eur J Clin Pharmacol       Date:  2012-04-05       Impact factor: 2.953

3.  Quantification of human uridine-diphosphate glucuronosyl transferase 1A isoforms in liver, intestine, and kidney using nanobore liquid chromatography-tandem mass spectrometry.

Authors:  David E Harbourt; John K Fallon; Shinya Ito; Takashi Baba; Joseph K Ritter; Gary L Glish; Philip C Smith
Journal:  Anal Chem       Date:  2011-12-05       Impact factor: 6.986

4.  Interethnic differences in UGT1A4 genetic polymorphisms between Mexican Mestizo and Spanish populations.

Authors:  Marisol López; Pedro Dorado; Alberto Ortega; Eva Peñas-Lledó; Nancy Monroy; Irma Silva-Zolezzi; Jesús Cobaleda; Alicia Gallego-Aguilera; María Elisa Alonso; Adrián Llerena
Journal:  Mol Biol Rep       Date:  2013-01-01       Impact factor: 2.316

5.  In vitro glucuronidation of fenofibric acid by human UDP-glucuronosyltransferases and liver microsomes.

Authors:  Jelena Tojcic; Marie-Odile Benoit-Biancamano; Michael H Court; Robert J Straka; Patrick Caron; Chantal Guillemette
Journal:  Drug Metab Dispos       Date:  2009-08-06       Impact factor: 3.922

6.  Refining the UGT1A haplotype associated with irinotecan-induced hematological toxicity in metastatic colorectal cancer patients treated with 5-fluorouracil/irinotecan-based regimens.

Authors:  Eric Lévesque; Anne-Sophie Bélanger; Mario Harvey; Félix Couture; Derek Jonker; Federico Innocenti; Erica Cecchin; Giuseppe Toffoli; Chantal Guillemette
Journal:  J Pharmacol Exp Ther       Date:  2013-02-05       Impact factor: 4.030

7.  Frequencies of UGT1A4*2 (P24T) and *3 (L48V) and their effects on serum concentrations of lamotrigine.

Authors:  Arne Reimers; Wenche Sjursen; Grethe Helde; Eylert Brodtkorb
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2014-12-10       Impact factor: 2.441

8.  Potential role of UGT1A4 promoter SNPs in anastrozole pharmacogenomics.

Authors:  Vineetha Koroth Edavana; Ishwori B Dhakal; Suzanne Williams; Rosalind Penney; Gunnar Boysen; Aiwei Yao-Borengasser; Susan Kadlubar
Journal:  Drug Metab Dispos       Date:  2013-01-31       Impact factor: 3.922

9.  A pharmacogenetics study of the human glucuronosyltransferase UGT1A4.

Authors:  Marie-Odile Benoit-Biancamano; Jean-Philippe Adam; Olivier Bernard; Michael H Court; Marie-Hélène Leblanc; Patrick Caron; Chantal Guillemette
Journal:  Pharmacogenet Genomics       Date:  2009-12       Impact factor: 2.089

10.  The UDP-glucuronosyltransferase (UGT) 1A polymorphism c.2042C>G (rs8330) is associated with increased human liver acetaminophen glucuronidation, increased UGT1A exon 5a/5b splice variant mRNA ratio, and decreased risk of unintentional acetaminophen-induced acute liver failure.

Authors:  Michael H Court; Marina Freytsis; Xueding Wang; Inga Peter; Chantal Guillemette; Suwagmani Hazarika; Su X Duan; David J Greenblatt; William M Lee
Journal:  J Pharmacol Exp Ther       Date:  2013-02-13       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.